Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Engineered Saccharomyces boulardii secreting Exendin-4
- Development stage
- Preclinical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
An advanced microbiome therapeutic consisting of genetically engineered probiotic yeast *Saccharomyces boulardii* that produces and secretes Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, directly in the gastrointestinal tract. The engineered yeast delivers the therapeutic peptide *in situ*, where it activates GLP-1 receptors in the gastrointestinal tract and intestinal sensory neurons to suppress appetite and promote weight loss. The mechanism involves interaction with the enteric nervous system (ENS) and vagus nerve. When tested in mice with diet-induced obesity and combined with cold exposure (8°C), this therapeutic suppressed appetite by 25% and promoted 4-fold higher weight loss compared to controls. The Exendin-4 produced by the engineered yeast demonstrated biological activity by inducing insulin secretion from pancreatic islets. The therapeutic is designed for oral administration, with the yeast producing Exendin-4 locally in the gut, avoiding the need for systemic circulation and frequent injections required by conventional GLP-1 receptor agonist therapies.
- Other names
- Sb-Exe4Sb-Exe-4Sb-Exe 4
02
Targets
Beyond the preview
Go deeper on Engineered Saccharomyces boulardii secreting Exendin-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Engineered Saccharomyces boulardii secreting Exendin-4.